Merck’s Molnupiravir reduces hospitalisation risk in COVID patients, says study
If authorised, Molnupiravir could be the first oral anti-viral medicine for COVID-19
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.